Delivery Order SPE2DB20D7061-SPE2DB24FSLG4
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,738.06 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes, a specialty medication. The contract has an ultimate completion date of December 19, 2024. This award is associated with Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,402.12 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes, a specialty medication used for various medical treatments. This award is part of Amerisourcebergen's larger $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the delivery of STELARA 90 MG/ML SYRINGEML. The $14,309.70 firm fixed price delivery order has a completion date of November 20, 2024. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and medical...
- This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical, a defense agency, to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $16,212.27 firm fixed price delivery order contract is for the supply of STELARA 90 MG/ML SYRINGEML, a pharmaceutical product. This award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA Troop Support Medical, valued...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,915.88 firm-fixed-price delivery order contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialty pharmaceutical product, to support military healthcare programs. The contract has an ultimate completion date of October 25, 2024. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $30,980.22 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes. The contract has an ultimate completion date of January 27, 2025. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $31,261.22 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML syringes, a specialty medication used for various medical treatments. The contract has an ultimate completion date of December 2, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $39,460.12 firm fixed-price delivery order is for the supply of STELARA 90 MG/ML SYRINGE syringes. The contract has an ultimate completion date of May 9, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division, which serves as the primary vehicle...
- This federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, was issued by the Defense Logistics Agency (DLA) for the procurement of STELARA 90 MG/ML SYRINGE. The $121,600.81 firm fixed-price delivery order has an ultimate completion date of January 29, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical, which serves as a primary vehicle for providing a...
- This federal contract award, valued at $10,381.90, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order for STELARA 90 MG/ML SYRINGEML, a specialty medication. The contract has an ultimate completion date of November 19, 2024 and a fixed-price pricing type. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
- SPE2DB20D7061Indefinite Delivery Contract
- SPE2DB20D7061-SPE2DB24FSLG4Delivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a pharmaceutical distribution company. The $31,505.16 delivery order contract is for the supply of STELARA 90 MG/ML SYRINGEML, a specialty medication. The contract has a firm fixed price pricing type and an ultimate completion date of November 17, 2023. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. The IDC enables the efficient procurement of a comprehensive range of pharmaceutical products and medical supplies to support military and veteran healthcare programs globally. The contract award did not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $31.5k | 11/16/23 |